Diabetic kidney disease (DKD) represents a growing public health burden and is the leading
cause of end-stage kidney diseases. In recent years, host-gut microbiota interactions have …

Diabetic Kidney Disease (DKD) is the leading cause of end stage renal disease (ESRD)
worldwide. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are now widely used in …

Type 2 diabetes mellitus (T2DM) is currently one of the most prevalent diseases, with as
many as 415 million patients worldwide. T2DM is characterized by elevated blood glucose …

BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …

Aim To assess the efficacy and safety of oral semaglutide, a novel glucagon‐like peptide‐1
receptor agonist, for patients with type 2 diabetes. Methods We searched Medline, Embase …

New-onset diabetes mellitus after transplantation (NODAT) is a frequent complication in
kidney allograft recipients. It may be caused by modifiable and non-modifiable factors. The …

The practical recommendations of the German Diabetes Society/Deutsche Diabetes
Gesellschaft (DDG) together with the German Society for Internal Medicine/Deutschen …

Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in
patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular …

Abstract Background and Aims The pharmacokinetics (PK) and single-dose tolerability of
tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide …

The development of chronic kidney disease (CKD) in people with diabetes is commonplace,
and is frequently associated with a significant and unfavourable impact on patient outcomes …